For colorectal cancer, the Immunoscore, based on the quantification of CD3+ and CD8+ T-cells in the tumor center (TC) and in the advancing tumor margin (margin), has turned out to be a better predictor of patient survival than histopathological methods, TNM staging, lymphovascular invasion, tumor differentiation or microsatellite instability status [11]. This evidence concerns the gene CD8A and neoplasm.